Drug intelligence / Profile preview

Phivax ChickPak

Development stage: Unknown
Lead developer: Phibro Animal Health
Modality: Vaccines & Immunotherapeutics
Administration: Spray, Injection

Overview

Phivax ChickPak is a trivalent veterinary vaccine developed by Phibro Animal Health Corporation specifically for the poultry industry. It is designed for hatchery-level administration to provide early-onset immunity against three significant avian pathogens: Newcastle Disease Virus (NDV), Infectious Bronchitis Virus (IBV), and Infectious Bursal Disease Virus (IBDV, also known as Gumboro disease). Introduced in 2019, the vaccine is part of a broader strategy to improve bird health and reduce reliance on antibiotics in poultry production. It is compatible with automated hatchery administration systems, including sprayers and injectors, allowing for efficient mass vaccination of day-old chicks.

Brand names: Phivax ChickPak

Beyond the preview

Go deeper on Phivax ChickPak.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phivax ChickPak.

Explore the full profile